US Stock MarketDetailed Quotes

RGLS Regulus Therapeutics

Watchlist
  • 1.7500
  • 0.00000.00%
Close Apr 1 16:00 ET
  • 1.7700
  • +0.0200+1.14%
Post 19:53 ET
115.93MMarket Cap-2.13P/E (TTM)

Regulus Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
60.85%50.04M
65.61%13.75M
87.20%15.21M
67.60%12.26M
19.77%8.83M
10.16%31.11M
19.73%8.3M
7.43%8.13M
1.95%7.32M
12.18%7.37M
Selling and administrative expenses
47.36%14.67M
60.58%4.07M
46.49%3.86M
68.92%3.95M
13.99%2.79M
1.30%9.96M
14.33%2.54M
17.04%2.64M
-5.19%2.34M
-15.43%2.44M
-General and administrative expense
47.36%14.67M
60.58%4.07M
46.49%3.86M
68.92%3.95M
13.99%2.79M
1.30%9.96M
14.33%2.54M
17.04%2.64M
-5.19%2.34M
-15.43%2.44M
Research and development costs
67.20%35.37M
67.83%9.67M
106.76%11.35M
66.98%8.31M
22.64%6.04M
14.89%21.15M
22.28%5.76M
3.35%5.49M
5.69%4.98M
33.87%4.93M
Operating profit
-60.85%-50.04M
-65.61%-13.75M
-87.20%-15.21M
-67.60%-12.26M
-19.77%-8.83M
-10.16%-31.11M
-19.73%-8.3M
-7.43%-8.13M
-1.95%-7.32M
-12.18%-7.37M
Net non-operating interest income expense
243.24%3.68M
299.58%955K
281.40%1.15M
304.29%1.23M
55.22%357K
1,392.77%1.07M
74.45%239K
2,408.33%301K
465.06%303K
254.36%230K
Non-operating interest income
129.04%3.84M
174.22%968K
163.24%1.15M
172.40%1.28M
5.54%438K
177.19%1.68M
6.01%353K
134.22%438K
496.20%471K
6,816.67%415K
Non-operating interest expense
-73.84%158K
-88.60%13K
-96.35%5K
-65.48%58K
-56.22%81K
-12.21%604K
-41.84%114K
-21.71%137K
3.70%168K
19.35%185K
Other net income (expense)
Income before tax
-54.34%-46.36M
-58.68%-12.79M
-79.73%-14.06M
-57.37%-11.04M
-18.63%-8.47M
-6.05%-30.04M
-18.63%-8.06M
-3.62%-7.82M
3.39%-7.01M
-6.27%-7.14M
Income tax
0.00%1K
0
0
0.00%1K
0.00%1K
0
0
1K
Net income
-54.34%-46.36M
-58.68%-12.79M
-79.73%-14.06M
-57.36%-11.04M
-18.63%-8.47M
-6.05%-30.04M
-18.63%-8.06M
-3.62%-7.82M
3.38%-7.01M
-6.25%-7.14M
Net income continuous Operations
-54.34%-46.36M
-58.68%-12.79M
-79.73%-14.06M
-57.36%-11.04M
-18.63%-8.47M
-6.05%-30.04M
-18.63%-8.06M
-3.62%-7.82M
3.38%-7.01M
-6.25%-7.14M
Minority interest income
Net income attributable to the parent company
-54.34%-46.36M
-58.68%-12.79M
-79.73%-14.06M
-57.36%-11.04M
-18.63%-8.47M
-6.05%-30.04M
-18.63%-8.06M
-3.62%-7.82M
3.38%-7.01M
-6.25%-7.14M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-54.34%-46.36M
-58.68%-12.79M
-79.73%-14.06M
-57.36%-11.04M
-18.63%-8.47M
-6.05%-30.04M
-18.63%-8.06M
-3.62%-7.82M
3.38%-7.01M
-6.25%-7.14M
Basic earnings per share
48.10%-0.82
48.72%-0.2
47.50%-0.21
54.05%-0.17
30.95%-0.29
15.05%-1.58
2.50%-0.39
20.00%-0.4
26.00%-0.37
8.70%-0.42
Diluted earnings per share
48.10%-0.82
48.72%-0.2
47.50%-0.21
54.05%-0.17
30.95%-0.29
15.05%-1.58
2.50%-0.39
20.00%-0.4
26.00%-0.37
8.70%-0.42
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 60.85%50.04M65.61%13.75M87.20%15.21M67.60%12.26M19.77%8.83M10.16%31.11M19.73%8.3M7.43%8.13M1.95%7.32M12.18%7.37M
Selling and administrative expenses 47.36%14.67M60.58%4.07M46.49%3.86M68.92%3.95M13.99%2.79M1.30%9.96M14.33%2.54M17.04%2.64M-5.19%2.34M-15.43%2.44M
-General and administrative expense 47.36%14.67M60.58%4.07M46.49%3.86M68.92%3.95M13.99%2.79M1.30%9.96M14.33%2.54M17.04%2.64M-5.19%2.34M-15.43%2.44M
Research and development costs 67.20%35.37M67.83%9.67M106.76%11.35M66.98%8.31M22.64%6.04M14.89%21.15M22.28%5.76M3.35%5.49M5.69%4.98M33.87%4.93M
Operating profit -60.85%-50.04M-65.61%-13.75M-87.20%-15.21M-67.60%-12.26M-19.77%-8.83M-10.16%-31.11M-19.73%-8.3M-7.43%-8.13M-1.95%-7.32M-12.18%-7.37M
Net non-operating interest income expense 243.24%3.68M299.58%955K281.40%1.15M304.29%1.23M55.22%357K1,392.77%1.07M74.45%239K2,408.33%301K465.06%303K254.36%230K
Non-operating interest income 129.04%3.84M174.22%968K163.24%1.15M172.40%1.28M5.54%438K177.19%1.68M6.01%353K134.22%438K496.20%471K6,816.67%415K
Non-operating interest expense -73.84%158K-88.60%13K-96.35%5K-65.48%58K-56.22%81K-12.21%604K-41.84%114K-21.71%137K3.70%168K19.35%185K
Other net income (expense)
Income before tax -54.34%-46.36M-58.68%-12.79M-79.73%-14.06M-57.37%-11.04M-18.63%-8.47M-6.05%-30.04M-18.63%-8.06M-3.62%-7.82M3.39%-7.01M-6.27%-7.14M
Income tax 0.00%1K000.00%1K0.00%1K001K
Net income -54.34%-46.36M-58.68%-12.79M-79.73%-14.06M-57.36%-11.04M-18.63%-8.47M-6.05%-30.04M-18.63%-8.06M-3.62%-7.82M3.38%-7.01M-6.25%-7.14M
Net income continuous Operations -54.34%-46.36M-58.68%-12.79M-79.73%-14.06M-57.36%-11.04M-18.63%-8.47M-6.05%-30.04M-18.63%-8.06M-3.62%-7.82M3.38%-7.01M-6.25%-7.14M
Minority interest income
Net income attributable to the parent company -54.34%-46.36M-58.68%-12.79M-79.73%-14.06M-57.36%-11.04M-18.63%-8.47M-6.05%-30.04M-18.63%-8.06M-3.62%-7.82M3.38%-7.01M-6.25%-7.14M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -54.34%-46.36M-58.68%-12.79M-79.73%-14.06M-57.36%-11.04M-18.63%-8.47M-6.05%-30.04M-18.63%-8.06M-3.62%-7.82M3.38%-7.01M-6.25%-7.14M
Basic earnings per share 48.10%-0.8248.72%-0.247.50%-0.2154.05%-0.1730.95%-0.2915.05%-1.582.50%-0.3920.00%-0.426.00%-0.378.70%-0.42
Diluted earnings per share 48.10%-0.8248.72%-0.247.50%-0.2154.05%-0.1730.95%-0.2915.05%-1.582.50%-0.3920.00%-0.426.00%-0.378.70%-0.42
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion with Explanatory Notes--------Unqualified Opinion--------

Market Insights

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
OKAY
833230
+29.96%
CHANGFU CO.,LTD
871396
+24.59%
Gansu Longshenrongfa Pharmaceutical Industry
300534
+20.05%
4
Tibet Duo Rui Pharmaceutical
301075
+20.02%
5
Chengda Pharmaceuticals
301201
+20.01%
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.

Discussing

Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings